161 related articles for article (PubMed ID: 25229170)
1. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.
Song J; Kim SW; Hong HJ; Lee MG; Lee BW; Choi TK; Lee SH; Yook KH
Clin Neuropharmacol; 2014; 37(5):136-41. PubMed ID: 25229170
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder.
Song J; Song DH; Jhung K; Cheon KA
Int Clin Psychopharmacol; 2011 Mar; 26(2):107-13. PubMed ID: 21127421
[TBL] [Abstract][Full Text] [Related]
3. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
4. Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.
Kim BN; Kim JW; Hong SB; Cho SC; Shin MS; Yoo HJ
Behav Brain Funct; 2010 Oct; 6():57. PubMed ID: 20929549
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
Lee SH; Kim SW; Lee MG; Yook KH; Greenhill LL; Fradin KN; Hong HJ
Psychiatry Res; 2011 Apr; 186(2-3):338-44. PubMed ID: 20863575
[TBL] [Abstract][Full Text] [Related]
6. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
[TBL] [Abstract][Full Text] [Related]
7. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
[TBL] [Abstract][Full Text] [Related]
8. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
Bruxel EM; Salatino-Oliveira A; Akutagava-Martins GC; Tovo-Rodrigues L; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Schmitz M; Arcos-Burgos M; Rohde LA; Hutz MH
Genes Brain Behav; 2015 Jun; 14(5):419-27. PubMed ID: 25989180
[TBL] [Abstract][Full Text] [Related]
9. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
10. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
Kim BN; Cummins TD; Kim JW; Bellgrove MA; Hong SB; Song SH; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
Int J Neuropsychopharmacol; 2011 Nov; 14(10):1399-410. PubMed ID: 21733227
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
12. CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics.
Özaslan A; Güney E; Ergün MA; Okur İ; Yapar D
J Mol Neurosci; 2021 Feb; 71(2):394-408. PubMed ID: 32691279
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
[TBL] [Abstract][Full Text] [Related]
14. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
15. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
16. Genetic imaging study with [Tc-
Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder.
Park S; Kim BN; Kim JW; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Psychopharmacol; 2014 Mar; 28(3):220-6. PubMed ID: 23471121
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
[TBL] [Abstract][Full Text] [Related]
19. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
20. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
